NextSense named a winner in the Health category for Fast Company's 2023 Next Big Things in Tech Awards. Read more here

CLINICAL

Commercially Available for Clinical Research

The richness of our data platform allows us to algorithmically extract many features and biomarkers of neural state and health that can be used across applications including neuro-health, disease management, and drug discovery — both in the clinic and more importantly, in the home.

Line

01 --- What is EEG and why it is important?

02 --- What is a digital twin

03 --- How do you collaborate with research partners?

Electroencephalography (EEG) measures brain waves that reflect the coordinated electrical activity of thousands of neurons. This method is used in clinical environments to detect abnormal brain activity and help with the diagnosis of different neurological conditions. During an EEG test, small metal disks are typically attached to the patient’s scalp and wired to an amplifier device for anywhere between 20 minutes (routine EEGs) to several days (ambulatory EEGs).

Although EEG has long been the gold standard for neurological examinations, it presents a number of technical challenges long recognized by clinicians. Capturing neuropathological events is quite rare during routine EEGs, and EEGs captured over multiple days are impractical long-term because traditional machines are incredibly bulky and limited to use in a clinical setting.

A digital twin is a virtual representation in data of something that exists in the real world, like your brain.

Our digital twin platform offers unprecedented insight into what affects brain health, including the neural correlates for things like screen time, and triggers for adverse neurological events like strokes, migraines, seizures and insomnia.

Our ML models decode millisecond level ERPs (event related potentials) can be accessed as APIs that allow us to build state-based applications and sophisticated alerting systems.

Our pipeline first contextualizes information through multimodal sensor fusion, then applies state of the art ML models to compare new data against existing sets and known patterns, then finally visualizes information for improved decision making.

This allows us to democratize access to personalized on-the-go neural insights that can support patient disease management for epilepsy, stroke, concussion and other neural anomalies. We want to put brain health insights in your pocket and with you wherever you go.

Our biomarker discovery platform can accelerate pharmaceutical drug development by tying real-world evidence to established endpoints. We can also help market access teams enhance their value dossiers, and we can help innovation teams determine the feasibility of new approaches to data collection and analysis.

For example, our partner Otsuka is developing novel biomarkers with NextSense that predict drug efficacy. Our partner UCB is using NextSense to predict seizure burden on a 24 hour basis.

We’d love to learn about your research goals anytime: hello@nextsense.io.

A Great Experience for Everyone

Line

Mobile ePro and Diary

The neural signals we collect from the ear is just the beginning. With a mobile app that enables in-depth cognitive assessments, self-reports, performance monitoring, and medication tracking, we see users in multiple dimensions.

Line

Obsessive About Privacy & Security

Data about your brain needs to be handled with great care. Privacy and security are, and always will be, a top priority organization-wide. All data collected by NextSense is HIPAA compliant, in accordance with GCP guidelines, and is end-to-end encrypted. We are 21 CFR Part 11 ready, and are regularly audited for NIST Cybersecurity Framework adherence.

CONDITION-SPECIFIC PACKAGES

In addition to general longitudinal monitoring and alerting capabilities, we offer condition-specific packages that users can subscribe to (and that researchers can leverage in their work).

Reducing the Risk of Stroke

Replace with: Many strokes are preceded by Transient Ischemic Attack—or TIAs—a temporary blockage of blood flow to the brain. TIAs can last only a few minutes. As a result, they often go ignored.

NextSense can alert people who are experiencing a TIA. If these people see a medical professional, they can reduce their chance of having a full blown stroke by 90%.

Empowering Individuals With Epilepsy

Individuals with epilepsy often feel like they’re at the mercy of their next seizure. Regardless of frequency, they’re plagued with the fear that they’ll have an attack at an important event like a wedding or that they’ll lose their driving privileges if they have a seizure while on the road.

Currently, there is no continuous remote monitoring and care solution on the market for epilepsy. Our biosensing earbuds can provide physicians with important information about how a patient is responding to a particular treatment in real time, enabling more effective medication titration for maximal benefit while minimizing side effects.

$32B

is the estimated healthcare cost of epilepsy treatment in the US per year.

30%

of adults with epilepsy experience resistance to drug treatment.

800K

people in the United States experience a stroke each year.

15%

of all strokes were preceded by transient attack (a TIA, or temporary blockage).

OUR PIPELINE

Arrow

Concussion Management

The shape of a concussion’s effects on the brain over time can vary significantly. We are currently working on both detection algorithms as well as real-time insights for medium and long-term concussion management for sports-related concussions as well those caused as a secondary effect of diseases like Parkinsons.

Arrow

Sleep Disorders and Aging

Tracking sleep EEG longitudinally may provide insight into how the brain is aging. We aim to identify early biomarkers of Alzheimer’s disease and other neurodegenerative conditions prior to onset of clinical symptoms, which could eventually lead to preventive intervention.

Arrow

Seizure Forecasting

As part of our R&D, we’re developing algorithms for seizure forecasting. This may provide patients with a daily seizure risk score, enabling them to modify certain behaviors and/or take an additional dose of medication.

Get on the Wait List
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
If you are a potential academic or commercial research partner, please send us an email: hello@nextsense.io.
Line

NextSense, Inc. (2024)

Privacy Policy